Genmab A/S reports results for the quarter ended September 30 - Earnings Summary

Genmab A/S

05/11/2026 18:03

Genmab A/S GMAB.CO reported quarterly adjusted earnings of $5.51​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of $6.46.  The mean expectation of twelve analysts for the quarter was for earnings of $3.54 per share. Wall Street expected results to range from $2.89  to $4.85 per share.
Revenue rose 16.1% to $1.19 billion from a year ago; analysts expected $1.19 billion. 
Genmab A/S's reported EPS for the quarter was $5.51​.
The company reported quarterly net income of $342 million.
Genmab A/S shares had risen by 52.7% this quarter and gained 76.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 10.2% in the last three months.​ 
In the last 30 days, four analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy," 1 "hold" and 3 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Genmab A/S is DKK4,050.00, about 10.2% above its last closing price of DKK3,635.00
This summary was machine generated from LSEG data November 5 at 06:03 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Sep. 30 2026 
3.54
5.51
Beat
Jun. 30 2026 
3.52
4.91
Beat
Mar. 31 2026 
1.38
0.83
Missed
Dec. 31 2025 
3.43
2.13
Missed